In this episode of Hospital Medicine Unplugged, we blitz Febrile Nonhemolytic Transfusion Reactions (FNHTRs)—the common post-transfusion fever that looks scary, wastes resources, but rarely bites. Diagnose fast, exclude the killers, treat supportively, and don’t give unnecessary meds or antibiotics.

We start with the definition & frequency: ≥1°C rise to ≥38°C or chills/rigors within 4 hours of transfusion, no other cause. Despite universal leukoreduction, FNHTRs still occur in ~0.1–0.3% of transfusions—especially with platelets.

Pathophysiology—two lanes:

Clinical picture: Fever ± chills/rigors during/soon after transfusion, no hemolysis signs (no back pain, hemoglobinuria, jaundice) and no allergic features (urticaria, wheeze). Most cases are mild and self-limited.

Do-firsts at bedside (every time):

Must-not-miss differentials (rule out fast):

Core labs/workup (send immediately):

Management—keep it simple (when serious causes excluded):

If fever is ≥39°C, rigors, hypotension, or organ dysfunction:

Prevention that actually works:

Monitoring & reporting:

Prognosis: Excellent for FNHTR—self-limited, minimal sequelae, low recurrence with leukoreduction/restrictive use. The danger lies in what FNHTR can mimic: AHTR, sepsis, TRALI—recognize and exclude these rapidly.

Bottom line: Stop the unit, exclude the killers, treat symptoms, and prevent the next one. Keep transfusions necessary, leukoreduced, and protocol-tight.

In this episode of Hospital Medicine Unplugged, we decode Euthyroid Sick Syndrome (ESS)—also known as Non-Thyroidal Illness Syndrome (NTIS)—the deadly lab mirage that looks like hypothyroidism but demands restraint, not replacement.

This syndrome appears in the sickest hospitalized patients—sepsis, trauma, burns, heart failure, renal or hepatic failure—where thyroid tests go haywire without true thyroid disease. The classic lab pattern? Low T3, normal or low T4, normal or low TSH, and often elevated reverse T3 from impaired T4→T3 conversion.

Mechanism check: Inflammation and stress cytokines (IL-1, IL-6, TNF-α) suppress deiodinases, dampen hypothalamic TRH, and alter hormone binding—all designed to slow metabolism and conserve energy during critical illness. Early on, peripheral conversion drops; later, the central axis shuts down. It’s not thyroid failure—it’s metabolic triage.

The twist? The deeper the thyroid suppression, the sicker the patient. ICU data show that low free T3 and high rT3 track with mortality, ventilator dependence, and longer ICU stays. In the elderly or malnourished, “low T3 syndrome” predicts frailty and poor outcomes. ESS is a biomarker of danger—not a call for levothyroxine.

Diagnosis pearls:

True hypothyroidism: TSH >20–25 µU/mL, low free T4, ± thyroid antibodies.

ESS/NTIS: Low T3, high rT3, non-elevated TSH.

Central hypothyroidism: Low or inappropriately normal TSH with low T4, often in pituitary disease.

Treatment trap: The American Thyroid Association and Endocrine Society agree—do not replace thyroid hormone in ESS. Randomized trials of T3 or T4 therapy show no survival benefit and even possible harm, especially in patients with renal failure or cardiac compromise. ESS reflects an adaptive slowdown, not a hormone deficiency. Treating it risks undoing the body’s protective metabolic brake.

Exceptions? Only in proven primary hypothyroidism, central hypothyroidism, or myxedema coma—not just low T3. Rare, controversial studies suggest theoretical benefit in “stunned myocardium” or severe cardiac dysfunction, but evidence is thin and practice remains conservative.

Management mantra:

Prognostic reality: ESS isn’t just a lab quirk—it’s a physiologic distress signal. The lower the T3, the higher the risk. But normalizing numbers won’t normalize outcomes; fixing the illness does.

So, the ESS take-home: Recognize the pattern. Resist the reflex. Respect the physiology.

In this episode of Hospital Medicine Unplugged, we tackle ischemic limb—act fast for ALI, plan smart for CLTI, save the patient and the leg.

We open with the two phenotypes:

Rapid bedside triage—decide viability, not vocabulary: inspect color/temp/mottling; check sensory & motor; palpate pulses; handheld Doppler (arterial/venous signals). Stage it (Rutherford for ALI; Rutherford/WIfI for CLTI) to set urgency.

Imaging that doesn’t slow you down: CTA or duplex to map anatomy only if the limb is viable or marginally threatened; unstable or immediately threatened limbs go straight to revascularization.

ALI do-firsts—time is muscle & nerve:

CLTI foundations—treat the patient and the pathway:

When to amputate: non-reconstructable disease, extensive necrosis, overwhelming infection, or prohibitive risk—prioritize a functional level and early rehab planning.

Pearls & pitfalls:

Discharge & durability: statin adherence, antiplatelet/antithrombotic plan, wound follow-up, smoking cessation, foot care, and a clear reintervention pathway. Multidisciplinary CLTI teams (vascular, cardiology, wound, podiatry, rehab, diabetes educators) improve limb salvage and survival.

We close with the hospitalist bundle: (1) Heparin now for ALI → Rutherford stage; (2) Call vascular early; (3) Imaging only if it won’t delay; (4) Choose revascularization by anatomy/urgency/comorbidity (endo vs. bypass vs. hybrid); (5) Post-flow monitor for compartments & electrolytes; (6) GDMT for PAD + smoking cessation; (7) Structured wound and infection plan; (8) Document WIfI and book follow-up.

Fast triage, decisive revascularization, and relentless risk-factor control—that’s how you keep legs (and lives) attached.

In this episode of Hospital Medicine Unplugged, we sprint through necrotizing fasciitis & Fournier’s gangrene—cut early, cut often, cover broadly, resuscitate hard.

We open with the do-firsts: STAT surgical consult and to-OR now when you see rapid progression, systemic toxicity, crepitus/necrosis, or failure to respond to antibiotics. Delays kill—plan repeat debridements q12–36h until only healthy, bleeding tissue remains. Imaging (CT) helps map disease only if stable and must never delay source control.

Empiric antibiotics—start immediately and go big for poly-/monomicrobial disease:

Supportive care that saves lives:

Surgical strategy—how we win:

Antibiotic stop line & course:

Adjuncts—use with judgment:

Risk triage & prognostics:

Bedside bundle you can deploy today:

Cut first, culture second, cover everything, and keep cutting until it’s clean.

In this episode of Hospital Medicine Unplugged, we tackle hospital malnutrition and refeeding syndrome—screen early, feed smart, monitor relentlessly.

We start with the inpatient playbook: screen every adult at admission (MNA-SF, MUST, NRS-2002), then confirm with GLIM and document the diagnosis. Build an individualized nutrition plan: counseling + the right route—oral first (precision nutrition + fortified ONS), enteral if the gut works, parenteral if it doesn’t. Day-to-day targets: ~20–30 kcal/kg and 0.8–1.5 g/kg protein, adjusted to disease burden and goals. Inflammation may blunt reversibility, so treat the illness while you nourish the patient.

Then we zoom in on refeeding syndrome (RFS)—the metabolic ambush of insulin-driven phosphate, potassium, and magnesium shifts causing hypophosphatemia, edema, arrhythmias, and respiratory failure. Thiamine demand spikes; miss it and you risk Wernicke’s.

Risk-stratify up front (older adults, chronic disease, low BMI, big weight loss, minimal intake, alcohol use, low baseline phosphate/magnesium). For high/very-high risk, start low and go slow:

If RFS hits: pause or reduce calories/fluids, replete electrolytes + thiamine, and re-advance gradually over 4–7 days. Enteral preferred when feasible; apply the same caution if PN is required.

Where the evidence lands:

Bedside do-firsts you can deploy today:

Pearls & pitfalls:

We close with a hospitalist RFS bundle: (1) universal screening → GLIM confirmation; (2) thiamine first, then low-start calories with stepwise advance; (3) electrolyte protocol + daily labs; (4) enteral-first strategy; (5) clear hold/reduce criteria (falling phosphate, edema, arrhythmia, rising CO₂); (6) written discharge nutrition plan.

Screen everyone, feed deliberately, and never refeed alone—bring the team.

In this episode of Hospital Medicine Unplugged, we tackle septic arthritis—recognize fast, tap the joint early, drain decisively, hit bugs smartly, and protect the cartilage.

We open with who gets it: elderly, diabetes, immunosuppressed, post-arthroscopy/joint surgery, prostheses, dialysis, active skin infection. Culprits are S. aureus (incl. MRSA), streptococci, and less often Gram-negatives—with MRSA = higher morbidity and mortality.

Call the diagnosis, don’t guess: acute monoarthritis (pain, swelling, warmth, ↓ROM) ± fever. CRP/ESR help but aren’t specific. The rule: aspirate before antibiotics (unless unstable). Send synovial fluid for Gram, culture, WBC + diff; >20,000/µL & >70% PMNs is highly suggestive. Culture in blood culture bottles to boost yield; add molecular assays (e.g., 16S/PCR) if culture-negative. Draw blood cultures. Imaging is adjunctive—US to find/guide effusion, MRI if osteomyelitis/deep infection—but never delay tap/therapy.

Risk-stratify for organisms & cover accordingly:

Source control—the nonnegotiable:

Antibiotic game plan & duration:

Monitoring that matters:

Medication pitfalls you don’t want to meet: delaying aspiration, starting antibiotics before cultures, underdosing MRSA/obesity, skipping Gram-negative coverage in high-risk hosts, forgetting to drain, or over-relying on imaging instead of a needle.

Special plays:

We close with the system bundle: (1) ED/ward “hot joint” pathway that auto-pages aspiration within hours; (2) order set: blood + synovial cultures (in BC bottles), cell count/diff, crystals, Gram ± PCR; (3) empiric antibiotics post-tap with MRSA logic and local antibiogram baked in; (4) drainage escalation checklist; (5) CRP-guided step-down and stop rules; (6) ID/Ortho co-management; (7) PJI branch with DAIR/revision criteria.

Fast aspiration, decisive drainage, culture-directed antibiotics, and relentless reassessment—that’s how you save the joint and the patient.

In this episode of Hospital Medicine Unplugged, we unpack fever of unknown origin (FUO) in hospitalized adults—define precisely, chase clues relentlessly, use PET-CT wisely, avoid reflex antibiotics.

We open with the definitions that matter: classic FUO (≥38.3°C on several occasions, ≥3 weeks, no diagnosis after appropriate evaluation) and nosocomial FUO (fever >48 hrs into hospitalization with nondiagnostic initial workup). Debate continues, but “reasonable diagnostic evaluation” beats rigid clocks when clinical sense demands it.

Patterns you’ll actually see: atypical presentations of common problems—catheter infections, pneumonia, UTI, intra-abdominal sources, drug fever, VTE/PE, postop complications—plus the big buckets: infection, malignancy, NIID/autoimmune, miscellaneous. Remember: up to one-third of ICU fevers are noninfectious.

The do-firsts: confirm true fever (repeat reliable temps), then history/physical that hunts clues—travel/exposures, procedures/devices, new meds, immunosuppression, focal symptoms, timing vs. admissions, and serial re-exams. Minimum workup: CBC, chem/LFTs, ESR/CRP, two sets blood cultures (central + peripheral if CVC), UA/urine culture, CXR, LDH/CK, RF/ANA, HIV, region-specific serologies (TB/CMV/EBV), and targeted abd/pelvic imaging when signs point that way. Clue-directed testing > shotgun testing.

ICU and postop twist: start with line cultures, CXR, and targeted CT/US if recent thoracic/abdominal surgery or localizing symptoms. Consider bedside lung ultrasound when the CXR is off. Keep a wide net for drug, neurogenic, and thromboembolic fevers.

Advanced moves (when baseline is unrevealing): FDG PET-CT shines at localizing occult infection/inflammation/malignancy, especially with elevated ESR/CRP and nondiagnostic CT—great for finding biopsy targets and sometimes reassuring when negative. Molecular diagnostics (multiplex PCR, broad-range 16S, NGS) help in culture-negative and immunocompromised hosts. Biopsy (lymph node, liver, temporal artery, bone marrow) when imaging or labs suggest a focal process.

Management principles we actually follow: avoid empiric antimicrobials or steroids unless neutropenic, immunocompromised, or clinically crashing—they mask diagnoses and rarely fix undifferentiated FUO. Individualize based on clues, consult ID/Rheum/Heme-Onc, and monitor closely for turns.

Prognosis is kinder than you think: ~75% resolve without a definitive label; mortality is low in undiagnosed FUO. But don’t miss the bad actors—endocarditis, abscess, TB, lymphoma, vasculitis—where timely diagnosis prevents damage.

Pitfalls you don’t want to meet: calling it FUO before a real exam, ignoring the med list (drug fever!), over-imaging without clues, emps that sterilize cultures, skipping central + peripheral cultures with CVC, and forgetting VTE/PE or thyroiditis on the differential.

We close with the system bundle: (1) standardized FUO admission set (cultures, ESR/CRP, CXR, UA) + clue-driven add-ons; (2) daily re-exam & temp review; (3) automatic line evaluation if CVC; (4) PET-CT when baseline + CT fail and markers are high; (5) image-guided biopsy of any focality; (6) hard stop on empiric therapy unless high-risk; (7) multidisciplinary huddles at 48–72 hrs; (8) documented de-labeling plan when benign course emerges.

Clue-first, PET-smart, biopsy-guided—resist reflex antibiotics, escalate thoughtfully, and let the story lead the testing.

In this episode of Hospital Medicine Unplugged, we blitz through VTE prevention in hospitalized patients—risk-stratify early, anticoagulate wisely, protect the bleeders, and hard-wire the system so the right patient gets the right prophylaxis at the right time.

We open with the do-firsts: Padua (medical), IMPROVE (medical/bleeding), Caprini (surgical) embedded in the admission workflow. High VTE risk + acceptable bleed risk = pharmacologic prophylaxis. High bleed risk = mechanical prophylaxis until it’s safe to anticoagulate.

Call the risk and act:

Treatment—build the anticoagulant backbone:

When not to anticoagulate—don’t miss the red flags: active major bleeding, recent high-risk procedure, platelets <50K, prior HIT, severe coagulopathy, intracranial lesions. If any are present, go mechanical and re-evaluate daily.

Mechanical moves:

Duration that sticks:

Extended prophylaxis reality check:

System plays that move the needle:

Monitoring & safety:

Special populations quick hits:

Medication pitfalls you don’t want to meet: underdosing in obesity, LMWH in severe CKD, unnecessary anticoagulation in low-risk patients, skipping daily reassessment, forgetting PPI in high GI-risk aspirin/NSAID use, and missing HIT.

We close with the bundle: (1) auto-score Padua/IMPROVE/Caprini at admission; (2) default LMWH/UFH orders with renal/weight logic; (3) auto-hold + IPC for high bleed risk; (4) daily mobility/bleed/VTE re-check; (5) ortho/cancer extended-duration pathways; (6) HIT surveillance + anti–Xa when needed; (7) patient education on meds, IPC, and red flags.

Risk-led, safety-first, system-powered VTE prevention—anticoagulate the right patients, protect the bleeders, and make it automatic.

In this episode of Hospital Medicine Unplugged, we cut through pericardial effusion in the inpatient setting—spot it fast with TTE, act early on tamponade, spare procedures when safe, and tailor to cause.

We open with the do-firsts: focused history/exam (dyspnea, chest pressure/fullness, pulsus paradoxus), ECG, CRP/ESR, CBC/chemistry ± troponin if myopericarditis suspected. TTE is first-line to confirm effusion, size it, and look for tamponade physiology (RA/RV diastolic collapse, plethoric IVC, respiratory inflow variation). If TTE is inconclusive, use CMR/CCT/TEE selectively for complex/loculated effusions or to chase secondary causes—routine CMR/CCT for tamponade assessment isn’t recommended.

Call tamponade when the clinical picture and echo line up; remember the physiology: rate of accumulation beats absolute volume—rapid fluid overwhelms pericardial compliance.

Action when it tips:

If there’s no tamponade:

When effusion rides with acute pericarditis, build the anti-inflammatory backbone:

Etiology plays—treat the cause:

Who stays and how we watch:

Pearls & pitfalls you don’t want to meet:

We close with the inpatient bundle that sticks: (1) TTE first ± selective CMR/CCT/TEE; (2) tamponade pathway (STAT echo → urgent echo-guided pericardiocentesis → full fluid studies); (3) no routine taps for stable effusions; (4) NSAID + colchicine for inflammatory cases, steroid-sparing strategy; (5) serial TTE for moderate/large effusions; (6) etiology-specific tracks (TB, uremia, malignancy, post-op) with multidisciplinary consults; (7) shared decision-making for pericardial window in recurrent/malignant disease.

Bottom line—imaging-led and risk-stratified: use TTE to steer, drain when unstable, treat the cause, and surveil the rest without over-proceduring.

In this episode of Hospital Medicine Unplugged, we sprint through inpatient gout—confirm the diagnosis, kill the flare fast (safely), and treat to target so patients stop bouncing back.

We open with the do-firsts: aspirate the joint or tophus when feasible to see MSU crystals under polarized light—doubles as a septic arthritis rule-out. If aspiration’s a no-go, lean on classic features and, when needed, ultrasound/DECT—but don’t anchor on serum urate alone (can be normal in flares). Map comorbidities/meds (CKD, HF, diabetes; diuretics, low-dose ASA, CNIs; CYP3A4/P-gp interactions).

Acute flare playbook—individualize, start early:

Hospital pitfalls you don’t want to meet: delayed treatment, stopping chronic urate-lowering therapy (ULT) on admission without cause, wrong colchicine dose, NSAIDs in CKD/HF, or forgetting drug–drug checks (macrolides, azoles, cyclosporine).

Treat-to-target that sticks (after the flare settles or continue if already on):

Patient & system moves: teach that gout is chronic, crystal-driven, and fixable with urate lowering; lifestyle tweaks help a bit but medication is the engine. Use the admission to (1) confirm gout, (2) start/titrate ULT when appropriate, (3) prescribe prophylaxis, (4) schedule labs/follow-up, and (5) hand over a clear flare plan.

Fast, crystal-proven, and target-driven—aspirate when you can, tailor the anti-inflammatories, and lock in SU <6 mg/dL so flares fade and tophi melt.